<DOC>
	<DOCNO>NCT01014962</DOCNO>
	<brief_summary>The purpose study determine upper dose albaconzole administer Thorough QTc study .</brief_summary>
	<brief_title>A Study Effects Increasing Doses Drug Treatment Nail Fungus</brief_title>
	<detailed_description>This study aim evaluate safety tolerability 5 day albaconazole dosing level exceed project therapeutic dose project therapeutic frequency , order identify upper dose administration TQTc study . It also aim assess pharmacokinetics multiple escalate dos albaconazole , assess effect multiple sustain dose high dos albaconazole ECG parameter .</detailed_description>
	<mesh_term>Onychomycosis</mesh_term>
	<criteria>Male female subject age 18 45 A body mass index ( BMI ) 18.5 30 kg/m2 . Good physical mental health . Vital sign .within acceptable range . Electrocardiogram ( 12lead ) least 5 minute supine position consider normal finding consider clinically significant investigator . . Nonsmoker least 6 month screen . Subject screen laboratory parameter within normal range unless consider clinically relevant principal investigator . . Subject able review understand informed consent , must sign independent ethic committee ( IEC ) /IRB approve informed consent form trialrelated procedure perform . Sexually active female childbearing potential must negative serum pregnancy test result screen . These subject must use medically acceptable method contraception receive protocolassigned product , expect continue use method contraception 90 day follow last dose study medication . A woman childbearing potential define one biologically capable become pregnant ; include perimenopausal woman le 2 year last menses . Women currently sexually active lactating must agree use 2 form nonhormonal contraception , become sexually active participate study , 90 day follow end participation study . Male subject and/or partner must use medically acceptable form contraception receiving protocolassigned product , 90 day follow last dose study medication . Subject willing able take assign clinical trial medication direct , comply clinical trial instruction , commit study visit . History intolerance ingredient study medication , relate drug , history relevant/clinically significant allergic reaction origin . Any disease physical condition , opinion investigator , could impact PK/pharmacodynamics drug could potentially compromise safety subject . Subject previously participate clinical study albaconazole . History drug , prescription medicine , alcohol abuse within past 2 year . Positive drug screen . History psychological emotional problem likely invalidate inform consent , could limit ability subject comply protocol requirement . Any drug treatment take within 14 day first drug intake within 5 halflives whichever longer . Participation another clinical trial , blood donation , significant blood loss le 30 day first intake study drug . Unsuitable vein repeat venipuncture . Subject know liver disease liver toxicity drug . Subject predose ECG dose QTcB QTcF interval &gt; 450 msec , abnormal morphology ECG , clinically serious arrhythmia . Subjects pregnant , breastfeeding , woman childbearing potential use adequate contraceptive plan conceive , male subject plan father child describe informed consent . Positive hepatitis B ( HBsAg ) hepatitis C ( Ab HCV ) HIV AIDS . Consumption exclude drug foodstuff within 72 hour dose . Subjects employee clinical research organization involve study , Stiefel , immediate family member . Subjects member household study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>June 2012</verification_date>
	<keyword>Pharmacokinetic</keyword>
	<keyword>tolerability</keyword>
	<keyword>multiple escalating dos</keyword>
</DOC>